Accepted for Publication: June 24, 2011.
Published Online: September 12, 2011. doi:10.1001/archneurol.2011.235
Author Contributions:Study concept and design: Shih and Bateman. Acquisition of data: Sigurdson, Shih, Kasten, Morris, Duntley, and Bateman. Analysis and interpretation of data: Huang, Potter, Santacruz, Ju, Kasten, Mintun, Duntley, and Bateman. Drafting of the manuscript: Huang, Potter, Kasten, and Bateman. Critical revision of the manuscript for important intellectual content: Potter, Sigurdson, Santacruz, Shih, Ju, Kasten, Morris, Mintun, Duntley, and Bateman. Statistical analysis: Huang, Potter, and Bateman. Obtained funding: Morris and Bateman. Administrative, technical, and material support: Potter, Sigurdson, Santacruz, Kasten, Morris, Mintun, Duntley, and Bateman. Study supervision: Duntley and Bateman.
Financial Disclosure: Eli Lilly provided antibodies for this research study.
Funding/Support: This work was supported by grants from the US National Institutes of Health (K08 AG027091-01, K23 AG 03094601, R-01-NS065667, P50 AG05681-22, and P01 AG03991-22), Washington University Clinical & Translational Science Award UL1 RR024992, grants from an anonymous foundation, a gift from Betty and Steve Schmid, The Knight Initiative for Alzheimer Research, The James and Elizabeth McDonnell Fund for Alzheimer Research, and a research grant from Eli Lilly for the purchase of antibodies.
Additional Contributions: We thank the Clinical Core of the The Charles F. and Joanne Knight Alzheimer's Disease Research Center for characterization of the older participants, and we thank the participants for their time and effort.